CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global nonprofit focused on blood cancer patient support, research, and advocacy, today announced a strategic collaboration to develop a comprehensive, patient-centered, real-world registry for pediatric acute myeloid leukemia (pAML), a rare and aggressive blood cancer.
Part of the Blood Cancer United Dare to Dream Project, the collaboration serves a dual purpose: empowering patients with their health-related data and information relevant to their journey and fueling broader scientific breakthroughs.
The collaboration will leverage olivia, Tempus’ AI-enabled personal health concierge app that centralizes health data into a single platform and uses AI to make that information accessible, actionable, and meaningful. Patients participating will receive access to olivia, which will provide tailored materials that utilize Blood Cancer United’s library of educational and patient support and access resources. Materials will be aligned to their disease subtype, treatment stage, and care needs – delivering timely, relevant information throughout their journey. olivia will also enable the collection of longitudinal electronic patient-reported outcomes and questionnaire data to inform and strengthen the registry.
olivia will be used alongside Lens, Tempus’ cloud-based analytics workspace that enables researchers to access and analyze multimodal, de-identified data. This approach will support the creation of one of the largest pAML registries to date, generating insights to drive new therapies and research breakthroughs.
The Blood Cancer United Dare to Dream Project is dedicated to transforming treatment and care for children with blood cancer. By funding groundbreaking research and clinical trial innovation—including PedAL, the first-ever pediatric acute leukemia Master Clinical Trial—the project actively shifts the landscape of pediatric oncology. Beyond the lab, Dare to Dream expands vital support services and leads advocacy efforts to ensure all children with blood cancers have access to affordable, quality healthcare.
“This collaboration will help patients and families now and lays the groundwork for an innovative, patient‑centered approach for the future. For rare disease subtypes like pediatric leukemia, it can be a challenge to enroll enough patients for both an experimental arm and a traditional control arm, which can delay or even prevent trials from starting,” says Gwen Nichols, M.D., Chief Medical Officer, Blood Cancer United. “Our vision is to combine patient‑reported outcomes with de‑identified medical and genomic data to create external control arms and other real‑world comparators, which will allow trials to run faster, let more children receive investigational therapies, and bring safer, more effective treatments to kids sooner.”
“Our work with the Blood Cancer United Dare to Dream Project is a significant step forward in our shared commitment to advance precision medicine, particularly in rare cancers like pediatric AML where high-quality, comprehensive data is desperately needed,” said Max Banaszak, COO of Data & Apps at Tempus. “By combining Tempus’ AI-enabled platform with Blood Cancer United’s deep connection to the patient community, we can create a powerful resource that we hope will improve both care and outcomes for children diagnosed with this devastating disease and accelerate research.”
About Blood Cancer United®
Blood Cancer United® (formerly The Leukemia & Lymphoma Society) is the largest global nonprofit focused on blood cancer patient support, research, and advocacy. The organization’s mission is to cure blood cancer and improve the quality of life of all patients and their families. To achieve it, Blood Cancer United brings together a community of people—patients and their families, volunteers, healthcare providers, scientists, staff, partners, fundraisers, and philanthropists—who believe all blood cancer patients deserve longer, fuller lives.
Since the organization’s founding in 1949, it has consistently evolved to better serve people affected by all 100-plus types of blood cancers—including leukemia, lymphoma, myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms.
Blood Cancer United offers free, trustworthy resources, personalized support, and community for anyone affected by blood cancer. The organization has invested more than $2 billion in research, which continues to increase survival rates. Blood Cancer United advocates nationally and locally for more accessible and affordable healthcare for all patients.
For support and to learn more, visit www.BloodCancerUnited.org. Patients can contact blood cancer information specialists at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET. Connect with the organization on Facebook, X, Instagram, LinkedIn and TikTok.
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the quality of Tempus’ research and publications; the contributions of Tempus’ research and findings to the larger scientific community and the use of Tempus’ products and services to advance clinical care for patients. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
Contacts
Hanah Heintzelman
[email protected]
